OPRX OptimizeRx Corp

OptimizeRx Sets First Quarter 2020 Conference Call for Monday, May 4, 2020 at 4:30 p.m. ET

OptimizeRx Sets First Quarter 2020 Conference Call for Monday, May 4, 2020 at 4:30 p.m. ET

ROCHESTER, Mich., April 16, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, will hold a conference call on Monday, May 4, 2020 at 4:30 p.m. Eastern time to discuss results for the first quarter ended March 31, 2020. The financial results will be issued in a press release prior to the call.

OptimizeRx management will host the call, followed by a question and answer period.

Date: Monday May 4, 2020

Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Toll-free dial-in number: 1-800-458-4148

International dial-in number: 1-323-794-2597

Conference ID: 2817301

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.

A replay of the call will be available after 7:30 p.m. Eastern time on the same day through May 25, 2020, as well as available for replay via the Investors section of the OptimizeRx website at .

Toll-free replay number: 1-844-512-2921

International replay number: 1-412-317-6671

Replay ID: 2817301

About OptimizeRx

OptimizeRx® (NASDAQ: OPRX), a digital health company, connects pharmaceutical companies to patients and providers, offering greater affordability, adherence and brand awareness at the point-of-care. As the nation’s largest digital platform connecting life sciences to the point-of-care, OptimizeRx provides a direct channel for pharma companies, payers, medtech, and medical associations to communicate with healthcare providers right within their workflow and also directly to patients.

The cloud-based solution supports patient adherence to medications and better healthcare outcomes with real-time access to financial assistance, prior authorization, education and critical clinical information. OptimizeRx provides more than half of the ambulatory patient market with access to these benefits through leading EHR platforms like Allscripts, Amazing Charts and Quest, and directly via its mobile communications platform and digital therapeutics SaaS platform.

For more information, follow the company on , or visit .

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

OptimizeRx Contact

Doug Baker, CFO

Tel (248) 651-6568 x807

Media Relations Contact

Maira Alejandra, Media Relations Manager

Tel (248) 651-6568 x807

Investor Relations Contact

Ron Both, CMA

Tel (949) 432-7557

EN
16/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fi...

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HC...

 PRESS RELEASE

OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) R...

OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2025. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibilities as a corporate ci...

 PRESS RELEASE

OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, a...

OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, follow...

 PRESS RELEASE

OptimizeRx Corporation Announces Plan for Additional Board of Director...

OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx’s ongoing process to refresh and expand its board of directors (the “Board”), it intends to appoint a new independent director to its Board of Directors during the second half of this year.  With the appointment of a new independent ...

 PRESS RELEASE

OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial ...

OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch